These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22984091)

  • 1. Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats.
    Yamazaki T; Izumi Y; Nakamura Y; Yamashita N; Fujiki H; Osada-Oka M; Shiota M; Hanatani A; Shimada K; Iwao H; Yoshiyama M
    Circ Heart Fail; 2012 Nov; 5(6):794-802. PubMed ID: 22984091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolvaptan attenuates left ventricular fibrosis after acute myocardial infarction in rats.
    Yamazaki T; Nakamura Y; Shiota M; Osada-Oka M; Fujiki H; Hanatani A; Shimada K; Miura K; Yoshiyama M; Iwao H; Izumi Y
    J Pharmacol Sci; 2013 Sep; 123(1):58-66. PubMed ID: 24005048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction.
    Udelson JE; Bilsker M; Hauptman PJ; Sequeira R; Thomas I; O'Brien T; Zimmer C; Orlandi C; Konstam MA
    J Card Fail; 2011 Dec; 17(12):973-81. PubMed ID: 22123358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure.
    Goldsmith SR; Gilbertson DT; Mackedanz SA; Swan SK
    J Card Fail; 2011 Dec; 17(12):982-9. PubMed ID: 22123359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Suzuki K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2007 Nov; 74(10):1466-75. PubMed ID: 17720144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central infusion of aldosterone synthase inhibitor attenuates left ventricular dysfunction and remodelling in rats after myocardial infarction.
    Huang BS; White RA; Ahmad M; Tan J; Jeng AY; Leenen FH
    Cardiovasc Res; 2009 Feb; 81(3):574-81. PubMed ID: 18689429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.
    Morooka H; Iwanaga Y; Tamaki Y; Takase T; Akahoshi Y; Nakano Y; Fujiki H; Miyazaki S
    Circ Heart Fail; 2012 Jul; 5(4):484-92. PubMed ID: 22628529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure.
    Wada K; Fujimori A; Matsukawa U; Arai Y; Sudoh K; Yatsu T; Sasamata M; Miyata K
    Eur J Pharmacol; 2005 Jan; 507(1-3):145-51. PubMed ID: 15659304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
    Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C;
    Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophage colony-stimulating factor treatment after myocardial infarction attenuates left ventricular dysfunction by accelerating infarct repair.
    Yano T; Miura T; Whittaker P; Miki T; Sakamoto J; Nakamura Y; Ichikawa Y; Ikeda Y; Kobayashi H; Ohori K; Shimamoto K
    J Am Coll Cardiol; 2006 Feb; 47(3):626-34. PubMed ID: 16458148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure.
    Watanabe K; Dohi K; Sugimoto T; Yamada T; Sato Y; Ichikawa K; Sugiura E; Kumagai N; Nakamori S; Nakajima H; Hoshino K; Machida H; Okamoto S; Onishi K; Nakamura M; Nobori T; Ito M
    J Cardiol; 2012 Dec; 60(6):462-9. PubMed ID: 23068288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
    Onogawa T; Sakamoto Y; Nakamura S; Nakayama S; Fujiki H; Yamamura Y
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S67-76. PubMed ID: 22120095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat.
    See F; Thomas W; Way K; Tzanidis A; Kompa A; Lewis D; Itescu S; Krum H
    J Am Coll Cardiol; 2004 Oct; 44(8):1679-89. PubMed ID: 15489104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impairment of cardiac function and remodeling induced by myocardial infarction in rats are attenuated by the nonpeptide angiotensin-(1-7) analog AVE 0991.
    Zeng WT; Chen WY; Leng XY; Tang LL; Sun XT; Li CL; Dai G
    Cardiovasc Ther; 2012 Jun; 30(3):152-61. PubMed ID: 21167013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.
    Udelson JE; McGrew FA; Flores E; Ibrahim H; Katz S; Koshkarian G; O'Brien T; Kronenberg MW; Zimmer C; Orlandi C; Konstam MA
    J Am Coll Cardiol; 2007 Jun; 49(22):2151-9. PubMed ID: 17543634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
    Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diet with isolated soy protein reduces oxidative stress and preserves ventricular function in rats with myocardial infarction.
    Hagen MK; Lehenbauer-Lüdke AR; Paludo AC; Schenkel P; Gonçalves L; Fernandes TG; Caron R; Llesuy S; Mill JG; Belló-Klein A
    Nutr Metab Cardiovasc Dis; 2009 Feb; 19(2):91-7. PubMed ID: 18571392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial.
    Udelson JE; Orlandi C; Ouyang J; Krasa H; Zimmer CA; Frivold G; Haught WH; Meymandi S; Macarie C; Raef D; Wedge P; Konstam MA; Gheorghiade M
    J Am Coll Cardiol; 2008 Nov; 52(19):1540-5. PubMed ID: 19007589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.